DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Branaplam
Branaplam
Volume 37 Number 10
The SMA Market: Assessing the Unknowns ❚ MARKET ACCESS: When Disease Dynamics Change the SMA Market: Assessing the Unknowns
Innovationsreport 2020 Kurzfassung
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
2018 年全球新药研发报告——第2 部分: 趋势与挑战(Ⅴ) Areport Of
2021 National Veterinary Scholars Symposium
Results from the Muscular Dystrophy Association DMD Clinical Research Network
Spinal Muscular Atrophy a Devastating Disease Now Has 2 Approved Breakthrough Treatments Available
Spinal Muscular Atrophy New Drug Evaluation: Onasemnogene Abeparvovec, Suspension for Intravenous Infusion
A View Into Upcoming Specialty & Traditional Drugs
Annexes to the Annual Report of the European Medicines Agency 2018
Download Master-Thesis (PDF, 1
Drug Repurposing Compound Library Plus (96-Well)
Two Breakthrough Gene-Targeted Treatments for Spinal Muscular Atrophy: Challenges Remain
2020 Medicines in Development for Children
Payer Perspectives on the Treatment Landscape of Spinal Muscular Atrophy (SMA) Findings from the AMCP Market Insights Program
A New Era in the Management of Neuromuscular Disorders in Children and Adolescents
New and Developing Therapies in Spinal Muscular Atrophy: from Genotype to Phenotype to Treatment and Where Do We Stand?
Top View
RNA-Targeted Therapies and High-Throughput Screening Methods
How Does Risdiplam Compare in Infantile-Onset Spinal Muscular Atrophy (SMA)? Preliminary Indirect Treatment Comparisons Based on FIREFISH Part 1 Data
A View Into Upcoming Specialty and Traditional Drugs JANUARY 2019
New Data at AAN Reinforce Novartis Commitment to Transforming the Lives of People of All Ages Who Live with Neurological Conditions
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri